Pham M, Stoll G, Nieswandt B, Bendszus M, Kleinschnitz C. J Mol Med (Berl). 2012 Feb;90(2):119-26. Epub 2011 Sep 10. Ischemic stroke is a devastating disease which, in most cases, is caused by thrombotic occlusion of brain arteries. The molecular mechanisms involved in microvascular thrombus formation during focal cerebral ischemia are not well understood. As a consequence, the current antithrombotic [...]
View Post factor XII, fibrin, ischemic stroke, thromboembolismDi Cera E. Prog Mol Biol Transl Sci. 2011;99:145-84. Thrombosis is the most prevalent cause of fatal diseases in developed countries. An antithrombotic agent that can be administered to patients with severe acute thrombotic diseases without the risk of causing hemorrhage, as experienced with antithrombotic/thrombolytic therapy in the treatment of acute ischemic stroke or systemic anticoagulants [...]
View Post antithrombotic, ischemic stroke, protease-activated receptors, Protein C, protein C activation, thrombolytic therapy, thrombosisNieswandt B, Kleinschnitz C, Stoll G. J Physiol. 2011 Sep 1;589(Pt 17):4115-23. Epub 2011 Jul 18. Ischaemic stroke is a leading cause of death and disability worldwide. The complex cellular interactions leading from thromboembolic vessel occlusion to infarct development within the brain parenchyma in acute stroke are poorly understood, which translates into only one approved effective treatment, thrombolysis. [...]
View Post factor XII, ischemic stroke, von Willebrand factorBerny-Lang MA, Hurst S, Tucker EI, Pelc LA, Wang RK, Hurn PD, Di Cera E, McCarty OJ, Gruber A. Stroke. 2011 Jun;42(6):1736-41. Epub 2011 Apr 21. Abstract BACKGROUND AND PURPOSE: Treatment of ischemic stroke by activation of endogenous plasminogen using tissue plasminogen activator is limited by bleeding side effects. In mice, treatment of experimental ischemic stroke with activated protein C improves outcomes; however, activated [...]
View Post bleeding side effects, ischemic stroke, plasminogen activator, W215A, WE-thrombinMinnerup J. , Kleinschnitz C. Stroke 42(5):1193-4. Pub Date: 05/2011 Sudden occlusion of a brain artery by a blood clot represents the pivotal event in ischemic stroke. Consequently, most of the therapeutic effort during the acute stage of cerebral ischemia aims at resolving the thrombus to restore blood flow. Because the clot is the primary target of [...]
View Post clot, embolism, ischemic stroke, occlusive clotsSiegerink B, Govers-Riemslag JW, Rosendaal FR, Ten Cate H, Algra A. Circulation. 2010 Nov 2;122(18):1854-61. Epub 2010 Oct 18. Classically, intrinsic coagulation proteins are thought to have a minor role in hemostasis. Recently, these proteins, especially FXII, were implicated as possible key players in the pathogenesis of arterial thrombosis. This study aims to determine the risks of arterial thrombosis conferred [...]
View Post factor XI, factor XII, ischemic stroke, protein activationPham M, Kleinschnitz C, Helluy X, Bartsch AJ, Austinat M, Behr VC, Renné T, Nieswandt B, Stoll G, Bendszus M. Neuroimage. 2010 Feb 15;49(4):2907-14. Epub 2009 Dec 1. Intrinsic coagulation factor XII deficient (FXII(-/-)) mice are protected from ischemic stroke. To elucidate underlying mechanisms we investigated the early ischemic period in vivo by multimodal magnetic resonance imaging (MRI) at 17.6 Tesla. Cerebral ischemia was induced [...]
View Post fXII, ischemic strokeSalomon O, Steinberg DM, Koren-Morag N, Tanne D, Seligsohn U. Blood. 2008 Apr 15;111(8):4113-7. Epub 2008 Feb 11. Inherited disorders of hemostasis are natural models for investigating mechanisms of thrombosis and development of antithrombotic therapy. Because mice with total factor XI deficiency are protected against ischemic stroke and do not manifest excessive bleeding, we investigated the incidence of ischemic stroke [...]
View Post factor XI, ischemic strokeBerny-Lang MA, Hurst S, Tucker EI, Pelc LA, Wang RK, Hurn PD, Di Cera E, McCarty OJ, Gruber A. Arterioscler Thromb Vasc Biol. 2008 Feb;28(2):329-34. Epub 2007 Oct 25. Treatment of ischemic stroke by activation of endogenous plasminogen using tissue plasminogen activator is limited by bleeding side effects. In mice, treatment of experimental ischemic stroke [...]
View Post E217A, endogenous plasminogen, endogenous protein C, ischemic stroke, plasminogen activator, Protein C, W215A, WE treatmentFisher M, Fernandez JA, Ameriso SF, Xie D, Gruber A, Paganini-Hill A, Griffin JH. Stroke. 1996 Jul;27(7):1163-6. Abstract BACKGROUND AND PURPOSE: Resistance to activated protein C (APC), a natural plasma anticoagulant, is the most common identifiable risk factor for venous thromboembolic disease. One point mutation in coagulation factor V that renders it APC-resistant is found in >90% of APC-resistant venous thrombosis patients. [...]
View Post Activated Protein C, ischemic stroke, Protein C, protein C activation